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 Abstract 
Purpose: Bisphosphonate, tetracyclines and spironolactone use has been shown to increase gastro-
esophagealoesophageal inflammation, an accepted risk factor for cancer. We explore whether use of 
these medications is associated with an increased risk of gastro-esophagealoesophageal cancer. 
 
Methods: A nested case-control study was conducted using the Primary Care Clinical Information 
Unit (PCCIU) database from Scotland. Cases with oesophagealesophageal or gastric cancer between 
1999 and 2011 were matched to up to five controls on age, gender, year of diagnosis and GP 
practice. Medication use was ascertained using electronic prescribing records. Conditional logistic 
regression was used to calculate odds ratios (ORs) for the association between medication use and 
cancer risk after adjustment for potential confounders including medication use and comorbidities.  
 
Results: A slightly higher proportion of gastro-esophagealoesophageal cancer cases received 
bisphosphonates (3.9% vs. 3.5%), tetracycline (6.0% vs. 6.0%) and spironolactone (1.4% vs. 1.1%) 
compared with the controls.  The adjusted odds ratios for the association between gastro-
esophagealoesophageal cancer and bisphosphonates, tetracycline and spironolactone were 1.04 
(95% CI: 0.84, 1.30), 0.99 (95% CI: 0.83, 1.17) and 1.06 (95% CI: 0.74, 1.51) respectively. Further 
analysis revealed bisphosphonates were associated with increased oesophagealesophageal cancer 
risk (1.33, 95% CI: 1.02, 1.74) and reduced gastric cancer risk (0.69, 95% CI: 0.48, 1.01), although 
there was no obvious dose-response relationship. 
 
Conclusions: There is little evidence that that the use of bisphosphonate, tetracycline or 
spironolactone is associated with increased risk of gastro-esophagealoesophageal cancer. Our 
findings should provide some reassurance to GPs that these widely-used medications are safe with 
respect to gastro-esophagealoesophageal cancer risk. 
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 Introduction 
Oesophagealesophageal and gastric cancer are among the most common cancers in the UK with 
7,300 and 5,300 new cases diagnosed annually.(1) Prognosis is extremely poor with around 55% of 
patients dying within one year of diagnosis(2). The role of inflammation in cancer is well established 
and various mechanisms have been proposed to explain the connection between inflammation and 
cancer.(3, 4) Several studies have demonstrated that patients with reflux oesophagitis have much 
higher oesophagealesophageal cancer risk(5), most likely through the Barrett’s pathway.(6, 7) A 
similar mechanism of cell metaplasia could also account for the marked increase in gastric cancer 
risk among patients with ulceration.(8, 9) 
 
Bisphosphonates, tetracyclines and spironolactone are widely used medications with main 
indications of osteoporosis, infections/acne/rosacea and hypertension/cardiac failure, respectively. 
During 2015, approximately 8.2, 3.2 and 2.5 million were dispensed prescribed by English general 
practitioners respectively.(10) Long-term usage of these medications is common; for example the 
anti-fracture effects of some bisphosphonates are only realised after 36 months(11) and tetracycline 
treatment for acne can last indefinitely.(12)  Each of these medications has been associated with 
increased risk of gastro-esophagealoesophageal inflammation.  Specifically, bisphosphonates have 
been shown in case reports to cause severe esophagitis including inflammation and thickening of the 
esophagealoesophageal wall(13, 14); more recently the ?US Food and Drug Administration  reported 
23 cases of esophagealoesophageal cancer among bisphosphonate users.(15) Tetracyclines has have 
also been shown to cause oesophagitis(16, 17) with prospective studies demonstrating an increased 
risks of oesophagealoesophageal injury and ulceration(18), and case reports showing of tetracycline 
induced lesions.(19)  Similarly, spironolactone has been associated with inflammation of the 
stomach including increased risk of gastric ulcers(20), possibly due to impaired mucosal healing. (20, 
21) Despite the widespread and prolonged use of these medications, epidemiological studies have 
focusssed solely on bisphosphonates and gastro-esophagealoesophageal cancer risk(22), and have 
yet to assess investigate the impact of risks associated with tetracyclines and spironolactone use. 
 
Therefore, in a case-control study nested within a population-based primary care cohort from in 
Scotland, we investigated whether bisphosphonates, spironolactone or tetracyclines were 
associated with an increased risk of gastro-esophagealoesophageal cancer risk.
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 Methods 
Data 
We conducted a nested case-control study using the Primary Care Clinical Information Unit Research 
(PCCIUR) database. Between 1993 and 2011, Tthe PCCIUR contains collected computerised medical 
records from approximately 15% of the Scottish general practice population (over 2 million patients 
registered with 393 general practices that used the General Practice Administration Systems for 
Scotland, GPASS clinical system), and includes details on patient demographics (e.g. age, 
deprivation), primary care encounters, clinical diagnoses and prescriptions (all recorded using Read 
codes(needs a reference). Our study protocol to access the PCCIUR data was approved by the 
Research Applications and Data Management Team, University of Aberdeen. Ethical approval for our 
study was supplied by the Queen’s University Belfast, School of Medicine Ethics Committee 
(reference number: 15.43). 
Cases and controls 
Our primary outcome analysis was for gastro-esophagealoesophageal cancer (combined) sinceas 
classifying tumours arising close to the oesophagogastric junction is difficult, and guidance on this 
process evolved throughout the study period.(23, 24) However, separate site-specific estimates 
(esophagealoesophageal and gastric cancer) were also presented?calculated. Cases were defined as 
patients with a first-time esophagealoesophageal (Read code: B10..) or gastric (Read code: B11..) 
cancer diagnosis after 1st January 1999. Up to five controls were randomly selected for each case 
matched on age, gender, year of diagnosis and GP practice. The index date was defined as the 
diagnosis date of the case in each matched group.  The start of the exposure period was the latest of 
1st January 1996 (as prescriptions before this were less likely to be generated electronically) or the 
date of registration with the GP practice registration.  Additionally, the exposure period was 
truncated to ensure it was identical across the matched groups.(25) Cases and controls with an 
earlier cancer diagnosis (other than non-melanoma skin cancer), and those with less than three 
years of exposure prior to index date, were excluded. 
Definition of exposure 
We identified prescriptions of bisphosphonate, tetracyclines and spironolactone from electronic 
prescription records. We used the British National Formulary (August 2016 version) to compile a list 
of proprietary and generic drug names containing these compounds (Appendix 1). We excluded 
prescriptions before 1st January 1996 and those in the year prior to the index date (to prevent 
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reverse causation). We defined patients as users if they had at least one prescription during the 
exposure period. To enable the testing of dose-response relationships we calculated the total 
number of prescriptions received during the exposure period and split patients into lower (less than 
the median) and higher (more than the median) users. We conducted a separate analysis for 
nitrogen-containing bisphosphonates, as these have a more severe impact on oesophagitis, and 
alendronate, the most commonly prescribed bisphosphonate. 
 
Confounding factors 
We identified fourteen comorbidities (myocardial infarction, heart failure, peripheral vascular 
disease, cerebrovascular disease, connective tissue disease, dementia, chronic obstructive 
pulmonary disease, rheumatoid arthritis, peptic ulcer disease, diabetes, renal disease, leukaemia / 
lymphoma, metastatic cancer, liver disease) using GP diagnosis Read codes recorded during the 
exposure period. Use of aspirin and statins within the exposure period were identified from 
prescription records (Appendix 1) as associations with oesophagealoesophageal and/or gastric 
cancer have been identified previously.(26, 27) Lifestyle data including body mass index (not obese, 
obese), smoking status (never, ex, current) and alcohol use (none, low, high) were also available 
from GP recordsthe PCCIUR data.  
Statistical Analysis 
We calculated descriptive statistics  and comparing compared the demographics and clinical 
characteristics of the cases and controls. We used conditional logistic regression to estimate odds 
ratios (ORs) with 95% confidence intervals (CIs) for the association between medication use and 
gastro-esophagealoesophageal cancer.  The matched design of the study accounted for the effect of 
age, gender, general practice and year of diagnosis but additional adjustments were made for the 
potential confounders of statin use (yes/no), aspirin use (yes/no) and the presence of fourteen 
comorbidities (yes/no) using regression.  
 
Our primary analysis was complete case, however we performed additional sensitivity analysis using 
multiple imputation with chained equations (MICE) for smoking, alcohol consumption and BMI with 
age, gender and deprivation used in the imputation, separately for cases and controls, using chained 
ordered logit models. Briefly, MICE is a simulation-based approach for handling missing data which 
leads to valid statistical inferences.(28) Sensitivity analysis analyses were also conducted 
investigating the impact of excluding prescriptions in the two years prior to the index date (as 
opposed to one defined as in the main analysis) and defining medication users as patients with at 
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least three prescriptions (as opposed to one in the main analysis). Analyses was conducted using 
Stata version 13.(29)
 Results 
We identified 3,098 cases of gastro-esophagealoesophageal cancer (1,979 oesophagealoesophageal 
and 1,119 gastric cancer) (Table 1). An average of 4.8 controls existed for each case with a mean 
exposure period of 6.1 years (min 3.0, max 15.1). There were some potentially important differences 
between cases and controls. Most notably, a larger proportion of cases had a history of peptic ulcer 
disease (16.7% vs. 9.2%) and COPD (11.7% vs 8.5%), and the cases were much more likely to be 
current or ex-smokers (64.7% vs 55.3%), drink high levels of alcohol (7.5% vs. 5.3%) and have normal 
weight (85.8% vs 79.9%). The proportion of missing data for smoking status and alcohol 
consumption was 21.5% and 32.0% respectively. 
 
The main analysis is shown in Table 2.  Overall, 3.9% (122/3098) of cases and 3.5% (526/14937) of 
controls used bisphosphonates suggesting little association between bisphosphonate use and 
gastro-esophagealoesophageal cancer risk (adjusted OR= 1.04; 95% CI: 0.84, 1.30) (Table 2).  There 
was evidence of a 33% increased risk (adjusted OR= 1.33; 95% CI: 1.02, 1.774) increased risk of 
esophagealoesophageal cancer in bisphosphonate users but a reduction of 31% (adjusted OR= 0.69; 
95% CI: 0.48-1, 1.0152) in gastric cancer.  The association between bisphosphonates and 
esophagealoesophageal or gastric cancer did not appear to follow a dose-response relationship. 
 
Tetracycline was used by 6.0% (186/3098) of cases and 6.0% (894/14937) of controls and there was 
no evidence of association with gastro-esophagealoesophageal cancer risk (OR= 0.99; 95% CI: 0.83, 
1.17). Similarly, no significant associations were observed between tetracycline use and 
esophagealoesophageal (OR=1.00; 95% CI: 0.81, 1.24) and gastric cancer (OR=0.97; 95% CI: 0.73, 
1.29).  
 
Overall, 1.4% (43/3098) of cases and 1.1% (159/14937) of controls used spironolactone but there 
was little evidence of association after adjustment for confounders (OR=1.06; 95%: 0.74, 1.51). 
Again, there was little evidence of higher risk for oesophagealesophageal or gastric cancer alone, 
with adjusted odds ratios of 1.07 (95% CI: 0.69, 1.65) and 1.00 (95% CI: 0.52, 1.90) respectively. 
 
In general, our conclusions were little altered in sensitivity analyses shown in Table 3.  Similar 
associations were observed when prescriptions were excluded in the two years prior to diagnosis 
rather than one (to reduce the risk of reverse causality) and when the exposure definition of ‘ever 
Commented [IL20]: I’m not sure I agree with this. Yes 
over the total time period mentioned below there were 
more gastric cxs than oesophageal cxs but the data show 
an overall pattern of declining rates of gastric cancer and 
increasing rates of oesophageal cx. If you look at the 
Scotland data from 1999 to 2011 (our diagnosis dates), 
you get a total of 10,721 oesophageal and 10,667 gastric 
cxs. 
Commented [LM21]: There were 20,163 oesophageal 
cancers diagnosed in Scotland between 1990 and 2014 
(inclusive) and 22,103 gastric cancers, so clearly the site 
distribution in the PCCIU data is wrong – gastric cancers 
are being diagnosed as oesophageal. This is an argument 
for examining the associations with gastro-oesophageal 
cancer as a whole and it means that the site specific 
estimates are incorrect.  It does however weaken the 
study as we cannot really say anything about the 
associations with individual sites 
Commented [AL22]: Is the distribution of exposure 
years skewed?  If so, need to report median duration of 
exposure and IQR 
Commented [IL23]: Clarify what this actually means. 
Commented [LM24]: I think use the proportion obese 
 
AL:agree 
Commented [AL25]: Need to be consistent in the way 
you report the odds ration…either as percentages or 
proportions 
use’ was based upon three or more prescriptions rather than one. Additionally, adjusting for lifestyle 
factors (smoking, alcohol consumption, and obesity), either in a complete case analysis or when 
using MICE, resulted in similar estimates to the main analysis. We also found slightly larger, although 
still moderate, associations when restricting our analysis to nitrogen-containing bisphosphonates 
(OR=1.13; 95% CI: 0.89, 1.44), or alendronate alone (OR=1.11; 95% CI: 0.86, 1.44), compared to the 
main analysis which combined all bisphosphonates.
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 Discussion 
In this study of oesophagealoesophageal and gastric cancer cases and controls in a community-
based population, we found little evidence of an association between gastro-
esophagealoesophageal cancer risk and the use of bisphosphonates, tetracyclines or spironolactone. 
Although there was some evidence that bisphosphonates increased the risk of 
oesophagealoesophageal cancer, there was no obvious dose-response relationship and these 
increases were largely offset by a reduction in gastric cancer risk. 
Strengths and limitations 
The main strength of our study lies in the high-quality and nationally representative data on which it 
is based.(30)  It is the first study to investigate the effect of tetracycline and spironolactone on 
gastro-esophagealoesophageal cancer risk and has found no evidence of an increased risk, which is 
important and reassuring given the large numbers of patients who use these medications often for 
prolonged periods of time.could have important implications for clinical practice. We used 
prescribing data collected as part of routine clinical care, in many cases, several years before the 
onset of esophagealoesophageal or gastric cancer which accurately reflects GP prescribing practices 
and negates the risk of recall bias.  Although a weaknesses of this approach is that we do not know if 
patients used their prescribed medications, the main conclusions were similar when restricting our 
analysis to patients who received multiple prescriptions (in which non-compliance is likely to be less 
of an issue). Our study is observational and hence open to confounding; although we have controlled 
for many of the key determinants of cancer risk through the matched design and analysis (e.g. age, 
comorbidities and GP practice) some other risk factors, including ethnicity and nutrition, were not 
available.   Finally, although our study was large, including over 3,000 gastro-esophagealoesophageal 
cancers, investigating multiple medications may have increased the possibility of type 2 error. 
Comparisons with other research 
To our knowledge, this is the first study to investigate the impact of tetracyclines and spironolactone 
use on gastro-esophagealoesophageal cancer risk.  
 
Several studies have previously examined the effect of bisphosphonates on gastro-
esophagealoesophageal cancer risk. In agreement with our findings, two UK-based studies which 
combined the oesophagealoesophageal and gastric cancer sites together in a single analysis found 
no significant association(31, 32) with bisphosphonate use, while another Danish study reported a 
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37% decrease in risk.(33) Although a recent meta-analysis reported no significant association 
between bisphosphonate use and oesophagealoesophageal cancer risk(22), several individual 
studies have observed an association. For example, two UK-based studies reported a 30% and 18% 
increased risk of oesophagealoesophageal cancer among bisphosphonate users, which was broadly 
in line with the 33% effect size estimated in our study.(34, 35) Our finding of reduced gastric cancer 
incidence among bisphosphonate users was replicated by several other studies(34-36), including one 
which found a 39% reduction in the risk of gastric cancer(33), although a recent meta-analysis 
reported no overall effect.(22) Several studies investigating the effect of bisphosphonate use on 
cancer incidence, separately for both the oesophagealoesophageal and gastric sites, reported a 
similar pattern to our study (i.e. increased risk of oesophagealoesophageal cancer which was largely 
offset by a decreased risk of gastric cancer incidence).(34-36) 
 
Implications 
Bisphosphonate, tetracycline and spironolactone are widely used and effective treatments for a 
range of indications including osteoporosis, rosacea and fluid retention. Our study suggests that any 
inflammation caused by these medications does not substantially increase the risk of gastro-
esophagealoesophageal cancer, and GPs should not be unduly concerned about cancer risk when 
prescribing these treatments. 
 
It is unclear why bisphosphonate users had an increased risk oesophageal of oesophageal cancer risk 
in our study. Firstly, these results could represent a true causal association; bisphosphonates are 
well known to cause dyspepsia and other inflammatory changes (e.g. oesophagitis, mucosal 
abnormalities)(37) which could form an important part of the upper-gastrointestinal cancer 
pathway.(15) Perhaps more likely, particularly given our concurrent finding of lower gastric cancer 
risk among bisphosphonate users, is that these associations are at least partly driven by a form of 
ascertainment bias. One Danish study reported that, due to higher rates of gastrointestinal side 
effects, patients receiving bisphosphonates were more than twice as likely to undergo upper 
endoscopy (4.1% vs. 1.7%).(33) This could lead to earlier detection of oesophagealoesophageal 
cancer.  and more accurate classification of some oesophagealoesophageal tumours proximal to the 
oesophagogastric junction in bisphosphonate users, which would have otherwise been incorrectly 
recorded as gastric in origin.(33) 
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Conclusions 
Overall, our study provided little evidence that the use of bisphosphonate, tetracyclines or 
spironolactone are associated with increased risk of gastro-esophagealoesophageal cancer.  These 
findings should provide GPs and patients with some reassurance that these widely-used medications 
are safe with respect to gastro-esophagealoesophageal cancer risk.  
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 Tables and Figures 
Table 1: Characteristics of controls and cases with oesophagealoesophageal or gastric cancer 
 Cases Controls 
Count 3,098 14,937 
At Risk Years (Min, Max) 6.1 (3.0,15.1) 6.1 (3.0,15.1) 
Year of Diagnosis   
1999-2003 1,063 (34.3%) 5,151 (34.5%) 
2004-2007 1,404 (45.3%) 6,741 (45.1%) 
2008-2011 631 (20.4%) 3,045 (20.4%) 
Mean Age (SD) 69.6 (11.3) 69.1 (11.2) 
0-39 26 (0.8%) 133 (0.9%) 
40-59 563 (18.2%) 2,807 (18.8%) 
60-79 1,886 (60.9%) 9,269 (62.1%) 
80+ 623 (20.1%) 2,728 (18.3%) 
Sex   
Female 1,095 (35.3%) 5,287 (35.4%) 
Male 2,003 (64.7%) 9,650 (64.6%) 
Smoking status   
Non-smoker 931 (35.3%) 5,147 (44.7%) 
Ex-smoker 898 (34.0%) 3,656 (31.8%) 
Current smoker 811 (30.7%) 2,708 (23.5%) 
Missing 458 3,426 
Alcohol Consumption   
No 551 (24.4%) 2,338 (23.3%) 
Low 1,534 (68.1%) 7,145 (71.3%) 
High 169 (7.5%) 532 (5.3%) 
Missing 844 4,922 
Obesity   
Not Obese 2,658 (85.8%) 11,932 (79.9%) 
Obese 440 (14.2%) 3,005 (20.1%) 
Deprivation Quintile   
1 (Least Deprived) 375 (12.3%) 1,776 (12.0%) 
2 555 (18.1%) 2,657 (18.0%) 
3 648 (21.2%) 3,137 (21.3%) 
4 748 (24.4%) 3,637 (24.6%) 
5 (Most Deprived) 734 (24.0%) 3,549 (24.1%) 
Missing 38 181 
Common Comorbiditiesa   
Connective Tissue Disease 1,377 (44.4%) 6,752 (45.2%) 
Peptic Ulcer Disease 518 (16.7%) 1,374 (9.2%) 
Diabetes 328 (10.6%) 1,422 (9.5%) 
COPD 361 (11.7%) 1,267 (8.5%) 
CVD 283 (9.1%) 1,214 (8.1%) 
Other Drug Use   
Aspirin 915 (29.5%) 4,217 (28.2%) 
Statin 753 (24.3%) 3,367 (22.5%) 
                                                          
a For brevity only the 5 most common comorbidities are listed. The full analysis included myocardial infarction, 
heart failure, peripheral vascular disease, cerebrovascular disease, connective tissue disease, dementia, 
chronic obstructive pulmonary disease, rheumatoid arthritis, peptic ulcer disease, diabetes, renal disease, 
leukaemia / lymphoma, metastatic cancer and liver disease 
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Table 2: Combined analysis of drug use risk with oesophagealoesophageal and gastric cancer risk 
 
Cases Controls 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI)b 
Gastro-esophagealoesophageal combined 
Bisphosphonates     
Never 2,976 (96.1%) 14,411 (96.5%) Ref Ref 
Ever 122 (3.9%) 526 (3.5%) 1.09 (0.88,1.34) 1.04 (0.84,1.30) 
Lower Usage (1-18) 64 (2.1%) 249 (1.7%) 1.22 (0.92,1.61) 1.17 (0.88,1.56) 
Higher Usage (19+) 58 (1.9%) 277 (1.9%) 0.97 (0.72,1.31) 0.93 (0.69,1.26) 
Tetracycline     
Never 2,912 (94.0%) 14,043 (94.0%) Ref Ref 
Ever 186 (6.0%) 894 (6.0%) 1.01 (0.86,1.20) 0.99 (0.83,1.17) 
Lower Usage (1) 104 (3.4%) 542 (3.6%) 0.93 (0.75,1.16) 0.91 (0.73,1.13) 
Higher Usage (2+) 82 (2.6%) 352 (2.4%) 1.14 (0.89,1.45) 1.11 (0.86,1.43) 
Spironolactone     
Never 3,055 (98.6%) 14,778 (98.9%) Ref Ref 
Ever 43 (1.4%) 159 (1.1%) 1.24 (0.88,1.75) 1.06 (0.74,1.51) 
Lower Usage (1-10) 21 (0.7%) 77 (0.5%) 1.26 (0.77,2.05) 1.09 (0.66,1.79) 
Higher Usage (11+) 22 (0.7%) 82 (0.5%) 1.23 (0.76,1.98) 1.03 (0.63,1.69) 
EsophagealOesophageal 
Bisphosphonates     
Never 1,895 (95.8%) 9,254 (97.0%) Ref Ref 
Ever 84 (4.2%) 289 (3.0%) 1.40 (1.08,1.81) 1.33 (1.02,1.74) 
Lower Usage (1-18) 47 (2.4%) 127 (1.3%) 1.78 (1.25,2.51) 1.71 (1.20,2.44) 
Higher Usage (19+) 37 (1.9%) 162 (1.7%) 1.09 (0.75,1.58) 1.03 (0.70,1.51) 
Tetracycline     
Never 1,858 (93.9%) 8,976 (94.1%) Ref Ref 
Ever 121 (6.1%) 567 (5.9%) 1.04 (0.85,1.29) 1.00 (0.81,1.24) 
Lower Usage (1) 66 (3.3%) 341 (3.6%) 0.95 (0.72,1.24) 0.92 (0.70,1.21) 
Higher Usage (2+) 55 (2.8%) 226 (2.4%) 1.19 (0.88,1.61) 1.13 (0.83,1.54) 
Spironolactone     
Never 1,949 (98.5%) 9,436 (98.9%) Ref Ref 
Ever 30 (1.5%) 107 (1.1%) 1.27 (0.84,1.92) 1.07 (0.69,1.65) 
Lower Usage (1-10) 13 (0.7%) 55 (0.6%) 1.05 (0.57,1.95) 0.94 (0.50,1.75) 
Higher Usage (11+) 17 (0.9%) 52 (0.5%) 1.50 (0.86,2.61) 1.20 (0.67,2.16) 
Gastric 
Bisphosphonates     
Never 1,081 (96.6%) 5,157 (95.6%) Ref Ref 
Ever 38 (3.4%) 237 (4.4%) 0.72 (0.50,1.04) 0.69 (0.48,1.01) 
Lower Usage (1-18) 17 (1.5%) 122 (2.3%) 0.65 (0.39,1.08) 0.62 (0.37,1.05) 
Higher Usage (19+) 21 (1.9%) 115 (2.1%) 0.80 (0.49,1.29) 0.77 (0.47,1.25) 
Tetracycline     
Never 1,054 (94.2%) 5,067 (93.9%) Ref Ref 
Ever 65 (5.8%) 327 (6.1%) 0.96 (0.72,1.27) 0.97 (0.73,1.29) 
Lower Usage (1) 38 (3.4%) 201 (3.7%) 0.90 (0.63,1.29) 0.90 (0.63,1.30) 
Higher Usage (2+) 27 (2.4%) 126 (2.3%) 1.04 (0.68,1.59) 1.09 (0.71,1.68) 
Spironolactone     
Never 1,106 (98.8%) 5,342 (99.0%) Ref Ref 
Ever 13 (1.2%) 52 (1.0%) 1.18 (0.63,2.21) 1.00 (0.52,1.90) 
Lower Usage (1-10) 8 (0.7%) 22 (0.4%) 1.78 (0.78,4.08) 1.43 (0.61,3.40) 
Higher Usage (11+) 5 (0.4%) 30 (0.6%) 0.75 (0.29,1.98) 0.68 (0.25,1.80) 
 
                                                          
b Adjusted for the presence of myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular 
disease, connective tissue disease, dementia, chronic obstructive pulmonary disease, rheumatoid arthritis, 
peptic ulcer disease, diabetes, renal disease, leukaemia / lymphoma, metastatic cancer and liver disease. 
Additionally conditioned on age, GP practice and year of diagnosis 
Commented [LM46]: Need to say that this is number 
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Table 3: Sensitivity analysis 
 
Cases Controls 
Unadjusted OR 
(95% CI) 
Adjusted OR 
(95% CI)c 
Bisphosphonates 
2- year exposure lag     
Never    3,001 (96.9%)   14,520 (97.2%) Ref Ref 
Ever       97 (3.1%)      417 (2.8%) 1.09 (0.86,1.37) 1.03 (0.81,1.31) 
Ever use ≥3 prescriptions     
Never    2,988 (96.4%)   14,442 (96.7%) Ref Ref 
Ever      110 (3.6%)      495 (3.3%) 1.05 (0.84,1.30) 1.00 (0.80,1.25) 
MI lifestyle adjusted     
Never    2,976 (96.1%)   14,411 (96.5%) Ref Ref 
Ever      122 (3.9%)      526 (3.5%) 1.09 (0.88,1.34) 1.03 (0.83,1.27) 
Lifestyle complete case     
Never    2,123 (96.0%)    9,218 (96.2%) Ref Ref 
Ever       88 (4.0%)      369 (3.8%) 1.00 (0.77,1.29) 0.93 (0.71,1.21) 
Nitrogen containing bisphosphonates  
Never    3,001 (96.9%)   14,551 (97.4%) Ref Ref 
Ever       97 (3.1%)      386 (2.6%) 1.18 (0.93,1.50) 1.13 (0.89,1.44) 
Alendronate only     
Never    3,015 (97.3%)   14,603 (97.8%) Ref Ref 
Ever       83 (2.7%)      334 (2.2%) 1.17 (0.91,1.51) 1.11 (0.86,1.44) 
Tetracycline 
2- year exposure lag     
Never    2,933 (94.7%)   14,200 (95.1%) Ref Ref 
Ever      165 (5.3%)      737 (4.9%) 1.10 (0.92,1.31) 1.07 (0.89,1.28) 
Ever use ≥3 prescriptions     
Never    3,049 (98.4%)   14,718 (98.5%) Ref Ref 
Ever       49 (1.6%)      219 (1.5%) 1.10 (0.80,1.50) 1.06 (0.77,1.46) 
MI lifestyle adjusted     
Never    2,912 (94.0%)   14,043 (94.0%) Ref Ref 
Ever      186 (6.0%)      894 (6.0%) 1.01 (0.86,1.20) 1.01 (0.85,1.20) 
Lifestyle complete case     
Never    2,067 (93.5%)    8,914 (93.0%) Ref Ref 
Ever      144 (6.5%)      673 (7.0%) 0.93 (0.76,1.13) 0.91 (0.75,1.12) 
Spironolactone 
2- year exposure lag     
Never    3,069 (99.1%)   14,805 (99.1%) Ref Ref 
Ever       29 (0.9%)      132 (0.9%) 1.02 (0.68,1.53) 0.83 (0.54,1.27) 
Ever use ≥3 prescriptions     
Never    3,061 (98.8%)   14,802 (99.1%) Ref Ref 
Ever       37 (1.2%)      135 (0.9%) 1.26 (0.87,1.83) 1.05 (0.71,1.54) 
MI lifestyle adjusted     
Never    3,055 (98.6%)   14,778 (98.9%) Ref Ref 
Ever       43 (1.4%)      159 (1.1%) 1.24 (0.88,1.75) 1.11 (0.77,1.60) 
Lifestyle complete case     
Never    2,175 (98.4%)    9,478 (98.9%) Ref Ref 
Ever       36 (1.6%)      109 (1.1%) 1.25 (0.83,1.89) 1.15 (0.75,1.77) 
                                                          
c Adjusted for the presence of myocardial infarction, heart failure, peripheral vascular disease, cerebrovascular 
disease, connective tissue disease, dementia, chronic obstructive pulmonary disease, rheumatoid arthritis, 
peptic ulcer disease, diabetes, renal disease, leukaemia / lymphoma, metastatic cancer and liver disease. 
Additionally conditioned on age, GP practice and year of diagnosis 
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Appendices 
Appendix 1: List of generic and proprietary drug names for each exposure and confounder 
compound 
Substance Name Drug Name 
Aspirin Asasantin, Aspirin, Caprin, Co-codaprin, Micropirin, Migramax, Nu-Seals 
Bisphosphonates Aclasta, Actonel, Alendronic acid, Aredia, Binosto, Bondronat, Bonefos, 
Bonviva, Clasteon, Clodronate, Didronel, Didronel PMO, Fosamax, Fosavance, 
Iasibon, Ibrandronic acid, Loron, Pamidronate, Risedronate, Zoledronic acid, 
Zometa 
Spironolactone Aldactide, Aldactone, Co-flumactone, Lasilactone, Spironolactone 
Statin Atorvastatin, Cholib, Crestor, Dorisin, Fluvastatin, Inegy, Lescol, Lipitor, 
Lipostat, Luvinsta, Pinmactil, Pravastatin, Rosuvastatin, Simvador, 
Simvastatin, Stefluvin, Zocor 
Tetracycline Acnamino, Aknemin, Democlocyline, Doxycycline, Doxylar, Efracea, 
Lymecycline, Minocin, Minocycline, Oxymycin, Oxytetracycline, Sebomin, 
Tetracycline, Tetralysal, Tigecycline, Tygacil, Vibramycin-D 
 
 Appendix 2: Comparison of characteristics for patients with oesophagealoesophageal and gastric 
cancer 
Substance 
Oesophagus  Gastric 
Cases Controls  Cases Controls 
Count 1,979 9,543  1,119 5,394 
At Risk Years (Min, Max) 6.1 (3.0,15.1) 6.1 (3.0,15.1)  6.1 (3.0,14.7) 6.1 (3.0,14.7) 
Year of Diagnosis      
1999-2003 665 (33.6%) 3,210 (33.6%)  398 (35.6%) 1,941 (36.0%) 
2004-2007 910 (46.0%) 4,382 (45.9%)  494 (44.1%) 2,359 (43.7%) 
2008-2011 404 (20.4%) 1,951 (20.4%)  227 (20.3%) 1,094 (20.3%) 
Mean Age (SD) 68.8 (11.3) 68.3 (11.1)  71.1 (11.4) 70.6 (11.2) 
0-39 10 (0.5%) 52 (0.5%)  16 (1.4%) 81 (1.5%) 
40-59 414 (20.9%) 2,070 (21.7%)  149 (13.3%) 737 (13.7%) 
60-79 1,207 (61.0%) 5,897 (61.8%)  679 (60.7%) 3,372 (62.5%) 
80+ 348 (17.6%) 1,524 (16.0%)  275 (24.6%) 1,204 (22.3%) 
Sex      
Female 615 (31.1%) 2,975 (31.2%)  480 (42.9%) 2,312 (42.9%) 
Male 1,364 (68.9%) 6,568 (68.8%)  639 (57.1%) 3,082 (57.1%) 
Smoking      
No 544 (32.3%) 3,232 (43.8%)  387 (40.5%) 1,915 (46.3%) 
Ex 578 (34.3%) 2,383 (32.3%)  320 (33.5%) 1,273 (30.7%) 
Current 562 (33.4%) 1,756 (23.8%)  249 (26.0%) 952 (23.0%) 
Missing 295 2,172  163 1,254 
Alcohol Consumption      
No 314 (21.7%) 1,430 (22.2%)  237 (29.3%) 908 (25.3%) 
Low 1,005 (69.5%) 4,638 (72.1%)  529 (65.5%) 2,507 (69.9%) 
High 127 (8.8%) 363 (5.6%)  42 (5.2%) 169 (4.7%) 
Missing 533 3,112  311 1,810 
Obesity      
Not Obese 1,703 (86.1%) 7,598 (79.6%)  955 (85.3%) 4,334 (80.3%) 
Obese 276 (13.9%) 1,945 (20.4%)  164 (14.7%) 1,060 (19.7%) 
Deprivation Quintile      
1 (Least Deprived) 242 (12.4%) 1,141 (12.1%)  133 (12.0%) 635 (11.9%) 
2 373 (19.1%) 1,791 (19.0%)  182 (16.4%) 866 (16.2%) 
3 406 (20.8%) 1,970 (20.9%)  242 (21.8%) 1,167 (21.8%) 
4 464 (23.8%) 2,259 (24.0%)  284 (25.6%) 1,378 (25.8%) 
5 (Most Deprived) 466 (23.9%) 2,249 (23.9%)  268 (24.2%) 1,300 (24.3%) 
Missing 28 133  10 48 
Common Comorbiditiesd      
Connective Tissue Disease 880 (44.5%) 4,281 (44.9%)  497 (44.4%) 2,471 (45.8%) 
Peptic Ulcer Disease 289 (14.6%) 880 (9.2%)  229 (20.5%) 494 (9.2%) 
Diabetes 197 (10.0%) 922 (9.7%)  131 (11.7%) 500 (9.3%) 
COPD 234 (11.8%) 787 (8.2%)  127 (11.3%) 480 (8.9%) 
CVD 166 (8.4%) 750 (7.9%)  117 (10.5%) 464 (8.6%) 
Other Drug Use      
Aspirin 557 (28.1%) 2,607 (27.3%)  358 (32.0%) 1,610 (29.8%) 
Statin 489 (24.7%) 2,124 (22.3%)  264 (23.6%) 1,243 (23.0%) 
 
                                                          
d For brevity only the 5 most common comorbidities are listed. The full analysis included myocardial infarction, 
heart failure, peripheral vascular disease, cerebrovascular disease, connective tissue disease, dementia, 
chronic obstructive pulmonary disease, rheumatoid arthritis, peptic ulcer disease, diabetes, renal disease, 
leukaemia / lymphoma, metastatic cancer and liver disease 
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